carmustine has been researched along with Lymphoma, Non-Hodgkin in 204 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma." | 9.07 | Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 9.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| " The median VAS scores of all patients were above 4 (moderate to severe pain) before the administration of transdermal fentanyl." | 7.74 | [Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation]. ( Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Lin, XB; Peng, YL; Wang, BF, 2007) |
| "We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma." | 7.69 | A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. ( Smith, RJ; Sweetenham, JW, 1995) |
| "The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years." | 6.82 | Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 5.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "Eighteen patients with malignant lymphoma, 10 non-Hodgkin's and 8 Hodgkin's, were treated with high-dose CVB (cyclophosphamide 4 x 1." | 5.29 | High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. ( Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S, 1993) |
| "We performed a clinical study of a triple-drug combination to evaluate its efficacy to prevent both acute and delayed emesis after high-dose chemotherapy with BEAM (BCNU [carmustine]+etoposide+ARA-C [cytarabine]+melphalan) before hematopoietic stem cell transplantation (HSCT) by comparison with a historical control group of patients treated with dexamethasone (dex) and ondansetron or palonosetron." | 5.15 | A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. ( Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A, 2011) |
| "We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma." | 5.07 | Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 5.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| "The Prospective Oral Mucositis Audit was an observational study in 197 patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) undergoing, respectively, high-dose melphalan or BEAM chemotherapy and autologous SCT at 25 European centres." | 3.75 | The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. ( Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vorkurka, S, 2009) |
| " The median VAS scores of all patients were above 4 (moderate to severe pain) before the administration of transdermal fentanyl." | 3.74 | [Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation]. ( Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Lin, XB; Peng, YL; Wang, BF, 2007) |
| "In the histiocytic lymphomas, BCNU added to CVP increases the percentage of CRs but it does so at the expense of considerable toxicity." | 3.74 | Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience. ( Bennett, JM; Carbone, PP; Ezdinli, E; Johnson, GJ; Lenhard, RE; Pocock, SJ, 1977) |
| " Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]." | 3.73 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005) |
| "We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma." | 3.69 | A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. ( Smith, RJ; Sweetenham, JW, 1995) |
| "Therapy with high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) plus autologous bone marrow transplantation has been extensively studied as treatment for patients with stage II or III breast cancer who have a 70% or greater risk of developing metastatic disease." | 3.68 | Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. ( Bearman, SI; Dufton, C; Fisher, JH; Jones, RB; Matthes, S; Shpall, EJ; Stemmer, SM; Stephens, JK, 1993) |
| "The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years." | 2.82 | Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016) |
| " These data may aid the design of studies to clarify optimal dosing and leukapheresis with pegfilgrastim." | 2.73 | A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. ( Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T, 2008) |
| " While BEAC and BEAM appears to have equal antitumour efficacy in patients with NHL, BEAM seems to be more toxic to the gastrointestinal tract." | 2.71 | BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. ( Jantunen, E; Kuittinen, T; Nousiainen, T, 2003) |
| "A decreased incidence of interstitial pneumonitis as well as a possible benefit in efficacy has been reported with lomustine (CCNU) compared to BCNU in the standard dose setting." | 2.70 | Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. ( Blume, KG; Chao, NS; Horning, SJ; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ; Wong, RM, 2001) |
| "Ten patients who relapsed are alive a median of 31 months (range, 6-47) after relapse." | 2.69 | High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. ( Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B, 1998) |
| " We reviewed the AUC of CPA in 470 patients who underwent pharmacokinetic monitoring of the drug." | 2.69 | Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Bearman, SI; Cagnoni, PJ; Jones, RB; Matthes, S; Murphy, J; Nieto, Y; Shpall, EJ; Xu, X, 1999) |
| "Fifteen patients with Hodgkin's disease (n = 10) and non-Hodgkin's lymphoma (n = 5) were studied." | 2.69 | Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. ( Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M, 2000) |
| "Six patients, four with Hodgkin's disease and two with non-Hodgkin lymphomas, developed leukemic complications, myelodysplasia (MDS) in four cases and overt acute myeloid leukemia (AML) in two." | 2.68 | High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. ( Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J, 1997) |
| "Fifty-six patients with non-Hodgkin's lymphoma (NHL, n = 26), Hodgkin's disease (HD, n = 17), or acute lymphoblastic leukemia (ALL, n = 13) with a history of previous radiation therapy were treated with cyclophosphamide (7." | 2.68 | High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. ( Anasetti, C; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Lilleby, K; Martin, P; Petersen, FB; Sanders, J; Weaver, CH, 1995) |
| "Of the patients with Hodgkin's disease, 2 (17%) achieved complete response (CR), and 3 (25%) attained a partial response (PR) for an overall response rate (CR + PR) of 42%." | 2.67 | Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study. ( Glick, JH; Gordon, LI; Horton, J; Rowe, JM; Smith, TJ; Spiers, AS; Weens, JH, 1991) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "Ninety-two patients with Hodgkin lymphoma and 47 with non-Hodgkin lymphoma were enrolled." | 1.43 | LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy. ( Gore, A; Gupta, A; Jain, R; Jeevangi, N; Kannan, S; Khattry, N; Nair, R; Saikia, T; Thippeswamy, R, 2016) |
| "Relationships between pharmacokinetic (PK) parameters of etoposide and toxicity survivals were reported in cancer patients treated at standard doses." | 1.42 | Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). ( Bachy, E; Casasnovas, O; Freyer, G; Guitton, J; Hénin, E; Ribrag, V; Salles, G; Sebban, C; Tilly, H; Tod, M; You, B, 2015) |
| "Fifteen patients with Hodgkin's or non-Hodgkin's lymphoma receiving HD conditioning chemotherapy and autologous SCT were assessed with respect to oral pain and severity of stomatitis on day -6, 0, +5 to +7, +13 to +15, and +100." | 1.37 | Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT. ( Cornely, OA; Keulertz, C; Lövenich, H; Rüping, MJ; Söhngen, D; Vehreschild, JJ; Wieland, U, 2011) |
| " The elimination half-life at steady state of rituximab in all patients was estimated to be 19." | 1.36 | Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ( Aarden, L; Baars, JW; Beijnen, JH; Huitema, AD; Tran, L, 2010) |
| "Fourteen (26%) patients with Hodgkin's lymphoma and 40 (74%) patients with non-Hodgkin's lymphoma were analyzed." | 1.36 | Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. ( Buset, EM; Haile, SR; Honegger, H; Knuth, A; Mischo, A; Pestalozzi, BC; Petrausch, U; Renner, C; Samaras, P; Schanz, U; Siciliano, RD; Stahel, RA; Stenner-Liewen, F; Stussi, G, 2010) |
| "The incidence of and risk factors for second cancer development in these patients have not been well studied." | 1.35 | Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. ( Crump, M; Keating, A; Kuruvilla, J; Pintilie, M; Seshadri, T; Tsang, R; Zadeh, S, 2009) |
| "Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion." | 1.35 | Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009) |
| "The Prospective Oral Mucositis Audit assessed the incidence, duration, and determinants of severe oral mucositis (OM; WHO oral toxicity scale grades 3 to 4) in patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) receiving high-dose conditioning chemotherapy before autologous stem-cell transplantation." | 1.35 | Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. ( Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vokurka, S, 2008) |
| "Cardiotoxicity is potentially the most threatening nonhaematological side effect of high-dose CY." | 1.33 | Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. ( Ala-Kopsala, M; Hartikainen, J; Husso-Saastamoinen, M; Jantunen, E; Kuittinen, T; Nousiainen, T; Sipola, P; Vuolteenaho, O, 2005) |
| "Despite the fact that follicular lymphomas are both chemo- and radiosensitive, the disease is generally non-curable." | 1.31 | Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. ( Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H, 2000) |
| " HDT appeared to be somewhat more toxic in the elderly patients: a higher peak CRP value (P = 0." | 1.31 | Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. ( Jantunen, E; Mahlamäki, E; Nousiainen, T, 2000) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 1.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "The probability of disease progression at 1 year for patients with chemoresistant and chemosensitive disease were 75% and 25%, respectively (P =." | 1.31 | Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. ( Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G, 2002) |
| "Cytogenetic analysis showed complex chromosomal abnormalities including 11q23 rearrangement, which is frequently found in topoisomerase II inhibitor-related hematologic malignancies." | 1.31 | A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma. ( Bahng, HS; Jang, GD; Jeong, YH; Ji, HS; Kim, EK; Kim, SH; Kim, SW; Kim, WK; Lee, JS; Park, CJ; Park, IG; Suh, CW; Suh, EJ, 2002) |
| " infusion via an ambulatory infusion pump with patient-activated intermittent dosing (BAD pump) for prevention of acute and delayed nausea/vomiting in patients receiving high-dose chemotherapy (HDC) for peripheral blood progenitor cell (PBPC) mobilization (MOB) or prior to autologous PBPC rescue." | 1.30 | Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. ( Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999) |
| " Within the NHL group, 21 patients were in 2nd or subsequent complete remission (CR) at transplant, 34 had sensitive disease and 11 resistant disease; 46 patients were transplanted in 1st CR due to the presence of > or = 2 adverse prognostic features at diagnosis or to a slow CR." | 1.30 | BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. ( Caballero, MD; Corral, M; del Cañizo, MC; García-Sanz, R; Gonzalez, M; Heras, I; Jean-Paul, E; León, A; Moraleda, JM; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vázquez, L; Vidriales, B, 1997) |
| "Twelve patients with Hodgkin's disease (HD) and 38 patients with non-Hodgkin's lymphoma (NHL) were mobilized with MIME/G-CSF." | 1.30 | Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. ( Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB, 1998) |
| "Eighteen patients with malignant lymphoma, 10 non-Hodgkin's and 8 Hodgkin's, were treated with high-dose CVB (cyclophosphamide 4 x 1." | 1.29 | High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. ( Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S, 1993) |
| "Patients with lymphoblastic lymphoma or diffuse undifferentiated lymphoma did poorly with CBV and should be offered alternative therapy." | 1.29 | Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. ( Antman, K; Ayash, L; Bierer, BE; Churchill, WH; Eder, JP; Elias, A; Gilliland, DG; Guinan, EC; Strawderman, M; Wheeler, C, 1993) |
| "A patient who developed pneumonitis immediately after the administration of carmustine (BCNU), within exactly the same field as previous irradiation, is presented." | 1.29 | Recall lung pneumonitis due to carmustine after radiotherapy. ( Agrawal, S; Geddes, DM; Gore, M; Thomas, PS, 1995) |
| "In eight patients with Hodgkin's disease the number of CFU-GM collected was less than 0." | 1.28 | Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas. ( Adam, M; Baruchel, A; Brice, P; Dombret, H; Gisselbrecht, C; Lepage, E; Marolleau, JP; Miclea, JM; Sitthy, X, 1992) |
| "Hydroxyurea is an antineoplastic drug with a broad spectrum of clinical activity and minimal nonhematopoietic toxicity." | 1.28 | High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent. ( Armitage, JO; Bierman, PJ; Glenn, LD; Kessinger, A; Reed, EC; Vaughan, WP, 1992) |
| "Forty patients with refractory solid tumors or non-Hodgkin's lymphoma were treated with high-dose cyclophosphamide, thiotepa, and carmustine (BCNU), followed by autologous stem cell rescue, in a phase I dose escalation study." | 1.28 | High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. ( Bitran, JD; Garner, M; Kaminer, LS; Moormeier, JA; Williams, SF, 1990) |
| "Seventy-seven Hodgkin's disease and non-Hodgkin's lymphoma (NHL) patients received high-dose etoposide in combination with cyclophosphamide and either fractionated total body irradiation (TBI) (n = 28) or carmustine (n = 49) prior to autologous bone marrow transplantation." | 1.28 | The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. ( Blume, KG; Chao, NJ; Hoppe, RT; Horning, SJ; Kwak, LW; Long, GD; Negrin, RS; O'Connor, P; Stallbaum, B, 1991) |
| "We treated 58 patients (28 with non-Hodgkin's lymphoma [NHL], 30 with Hodgkin's disease [HD]) at seven dose levels of CBV." | 1.28 | Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. ( Antin, JH; Ault, KA; Bubley, GJ; Churchill, WH; Come, SE; Rappaport, JM; Rosenthal, DS; Schnipper, LE; Smith, BR; Wheeler, C, 1990) |
| "Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation." | 1.28 | High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. ( Armitage, JO; Bierman, PJ; Kessinger, A; Landmark, JD; Smith, DM; Weisenburger, DD, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (9.80) | 18.7374 |
| 1990's | 69 (33.82) | 18.2507 |
| 2000's | 68 (33.33) | 29.6817 |
| 2010's | 40 (19.61) | 24.3611 |
| 2020's | 7 (3.43) | 2.80 |
| Authors | Studies |
|---|---|
| Sapelli, J | 1 |
| Filho, JS | 1 |
| Matias Vieira, GM | 1 |
| Moura, FL | 1 |
| Germano, JN | 1 |
| de Lima, VCC | 1 |
| Reiss, SN | 1 |
| Yerram, P | 1 |
| Modelevsky, L | 1 |
| Grommes, C | 1 |
| Cohen, YI | 1 |
| Lebel, E | 1 |
| Zimran, E | 1 |
| Shaulov, A | 1 |
| Stepensky, P | 1 |
| Grisariu, S | 1 |
| Avni, B | 1 |
| Ron-Magaña, AL | 1 |
| Fernandez-Vargas, OE | 1 |
| Barrera-Chairez, E | 1 |
| Ron-Guerrero, CS | 1 |
| Bañuelos-Ávila, AJ | 1 |
| Velasco, R | 1 |
| Mercadal, S | 1 |
| Vidal, N | 1 |
| Alañá, M | 1 |
| Barceló, MI | 1 |
| Ibáñez-Juliá, MJ | 1 |
| Bobillo, S | 1 |
| Caldú Agud, R | 1 |
| García Molina, E | 1 |
| Martínez, P | 1 |
| Cacabelos, P | 1 |
| Muntañola, A | 1 |
| García-Catalán, G | 1 |
| Sancho, JM | 1 |
| Camro, I | 1 |
| Lado, T | 1 |
| Erro, ME | 1 |
| Gómez-Vicente, L | 1 |
| Salar, A | 2 |
| Caballero, AC | 1 |
| Solé-Rodríguez, M | 1 |
| Gállego Pérez-Larraya, J | 1 |
| Huertas, N | 1 |
| Estela, J | 1 |
| Barón, M | 1 |
| Barbero-Bordallo, N | 1 |
| Encuentra, M | 1 |
| Dlouhy, I | 1 |
| Bruna, J | 1 |
| Graus, F | 5 |
| Khurana, A | 1 |
| Micallef, IN | 1 |
| LaPlant, BR | 1 |
| Patrick O'Neill, B | 1 |
| Habermann, TM | 2 |
| Ansell, SM | 1 |
| Inwards, DJ | 2 |
| Porrata, LF | 2 |
| Paludo, J | 1 |
| Bisneto, JCV | 1 |
| Johnston, PB | 1 |
| Kürzel, S | 1 |
| Blaudszun, AR | 1 |
| Stahl, L | 1 |
| Herbst, R | 1 |
| Kroschinsky, F | 1 |
| Birkmann, J | 2 |
| Hänel, A | 1 |
| Schaefer-Eckart, K | 1 |
| Ehninger, G | 1 |
| Fiedler, F | 1 |
| Bornhäuser, M | 1 |
| Fricke, S | 1 |
| Hänel, M | 1 |
| Kaji, FA | 1 |
| Martinez-Calle, N | 1 |
| Bishton, MJ | 1 |
| Figueroa, R | 1 |
| Adlington, J | 1 |
| O'Donoghue, M | 1 |
| Smith, S | 1 |
| Byrne, P | 2 |
| Paine, S | 1 |
| Sovani, V | 1 |
| Auer, D | 1 |
| James, E | 1 |
| Bessell, EM | 6 |
| Grainge, MJ | 1 |
| Fox, CP | 1 |
| Saleh, K | 1 |
| Danu, A | 1 |
| Koscielny, S | 2 |
| Legoupil, C | 1 |
| Pilorge, S | 1 |
| Castilla-Llorente, C | 1 |
| Ghez, D | 1 |
| Lazarovici, J | 1 |
| Michot, JM | 1 |
| Khalife-Saleh, N | 1 |
| Lapierre, V | 1 |
| Alenxandrova, K | 1 |
| Arfi-Rouche, J | 1 |
| Bourhis, JH | 3 |
| Ribrag, V | 3 |
| Ciochetto, C | 1 |
| Botto, B | 1 |
| Passera, R | 1 |
| Bellò, M | 1 |
| Benevolo, G | 1 |
| Boccomini, C | 1 |
| Castellino, A | 1 |
| Chiappella, A | 1 |
| Freilone, R | 1 |
| Nicolosi, M | 1 |
| Orsucci, L | 1 |
| Pecoraro, C | 1 |
| Pregno, P | 1 |
| Bisi, G | 1 |
| Vitolo, U | 2 |
| Sakellari, I | 2 |
| Gavriilaki, E | 1 |
| Bouziana, S | 1 |
| Constantinou, V | 1 |
| Mallouri, D | 2 |
| Vardi, A | 1 |
| Marvaki, A | 2 |
| Batsis, I | 2 |
| Sotiropoulos, D | 2 |
| Anagnostopoulos, A | 2 |
| Singer, S | 1 |
| Sharma, N | 1 |
| Dean, R | 1 |
| Zhao, Q | 1 |
| Abounader, D | 1 |
| Elder, P | 1 |
| Hofmeister, CC | 1 |
| Benson, DM | 1 |
| Rosko, A | 1 |
| Penza, S | 1 |
| Andritsos, L | 1 |
| Vasu, S | 1 |
| Jaglowski, S | 1 |
| William, BM | 3 |
| Bolwell, B | 1 |
| Pohlman, B | 1 |
| Kalaycio, M | 1 |
| Jagadeesh, D | 1 |
| Hill, B | 1 |
| Sobecks, R | 1 |
| Devine, SM | 2 |
| Majhail, NS | 1 |
| Efebera, YA | 1 |
| Allen, MS | 1 |
| Loberiza, FR | 1 |
| Bociek, RG | 1 |
| Bierman, PJ | 6 |
| Armitage, JO | 7 |
| Vose, JM | 3 |
| Rancea, M | 1 |
| Will, A | 1 |
| Borchmann, P | 1 |
| Monsef, I | 1 |
| Engert, A | 2 |
| Skoetz, N | 1 |
| Mei, M | 1 |
| Wondergem, MJ | 1 |
| Palmer, JM | 2 |
| Shimoni, A | 3 |
| Hasenkamp, J | 1 |
| Tsai, NC | 1 |
| Simpson, J | 1 |
| Nademanee, A | 3 |
| Raubitschek, A | 1 |
| Forman, SJ | 3 |
| Krishnan, AY | 1 |
| Ancochea, Á | 1 |
| García-Pallarols, F | 1 |
| Gimeno, E | 1 |
| Fernández-Rodriguez, C | 1 |
| Sánchez-González, B | 1 |
| Cioch, M | 1 |
| Jawniak, D | 1 |
| Kotwica, K | 1 |
| Wach, M | 1 |
| Mańko, J | 1 |
| Gorący, A | 1 |
| Klimek, P | 1 |
| Mazurkiewicz, E | 1 |
| Jarosz, P | 1 |
| Hus, M | 1 |
| Truelove, E | 1 |
| Fox, C | 1 |
| Robinson, S | 1 |
| Pearce, R | 2 |
| Perry, J | 1 |
| Kirkland, K | 1 |
| McQuaker, G | 1 |
| Pagliuca, A | 1 |
| Johnson, P | 1 |
| Russell, N | 3 |
| Cook, G | 1 |
| Bojic, M | 1 |
| Berghoff, AS | 1 |
| Troch, M | 1 |
| Agis, H | 1 |
| Sperr, WR | 1 |
| Widhalm, G | 1 |
| Wöhrer, A | 1 |
| Kalhs, P | 2 |
| Preusser, M | 1 |
| Rabitsch, W | 3 |
| Chen, YB | 1 |
| Lane, AA | 1 |
| Logan, B | 1 |
| Zhu, X | 1 |
| Akpek, G | 1 |
| Aljurf, M | 1 |
| Artz, A | 1 |
| Bredeson, CN | 1 |
| Cooke, KR | 1 |
| Ho, VT | 1 |
| Lazarus, HM | 4 |
| Olsson, R | 1 |
| Saber, W | 1 |
| McCarthy, P | 1 |
| Pasquini, MC | 2 |
| Apostolou, C | 1 |
| Konstantinou, V | 1 |
| Abela, EM | 1 |
| Douka, V | 1 |
| Karypidis, K | 1 |
| Iskas, M | 1 |
| Baliakas, P | 1 |
| Kaloyannidis, P | 1 |
| Yannaki, E | 1 |
| Kouvatseas, G | 1 |
| Smias, C | 1 |
| Caimi, PF | 1 |
| Silva Rondon, CH | 1 |
| Fu, P | 3 |
| Cooper, BW | 3 |
| Campagnaro, EL | 1 |
| Gerson, SL | 3 |
| Reese-Koc, J | 1 |
| Fox, R | 1 |
| Creger, RJ | 3 |
| de Lima, M | 1 |
| You, B | 1 |
| Salles, G | 4 |
| Bachy, E | 1 |
| Casasnovas, O | 1 |
| Tilly, H | 5 |
| Sebban, C | 4 |
| Hénin, E | 1 |
| Guitton, J | 1 |
| Tod, M | 1 |
| Freyer, G | 1 |
| Khattry, N | 1 |
| Gupta, A | 1 |
| Jain, R | 1 |
| Gore, A | 1 |
| Thippeswamy, R | 1 |
| Jeevangi, N | 1 |
| Kannan, S | 1 |
| Nair, R | 1 |
| Saikia, T | 1 |
| Flowers, CR | 1 |
| Costa, LJ | 1 |
| Le-Rademacher, J | 1 |
| Lill, M | 1 |
| Shore, TB | 1 |
| Vaughan, W | 1 |
| Craig, M | 1 |
| Freytes, CO | 2 |
| Shea, TC | 1 |
| Horwitz, ME | 1 |
| Fay, JW | 1 |
| Mineishi, S | 1 |
| Rondelli, D | 1 |
| Mason, J | 1 |
| Braunschweig, I | 1 |
| Ai, W | 1 |
| Yeh, RF | 1 |
| Rodriguez, TE | 1 |
| Flinn, I | 1 |
| Comeau, T | 1 |
| Yeager, AM | 1 |
| Pulsipher, MA | 1 |
| Bence-Bruckler, I | 1 |
| Laneuville, P | 2 |
| Bierman, P | 1 |
| Chen, AI | 1 |
| Kato, K | 1 |
| Wang, Y | 1 |
| Xu, C | 1 |
| Smith, AJ | 1 |
| Waller, EK | 1 |
| Philippe, L | 1 |
| Helias, P | 1 |
| Puyraveau, M | 1 |
| Boulahdour, H | 1 |
| Deconinck, E | 3 |
| Daguindau, E | 1 |
| Hohloch, K | 1 |
| Zeynalova, S | 1 |
| Chapuy, B | 1 |
| Pfreundschuh, M | 3 |
| Loeffler, M | 2 |
| Ziepert, M | 1 |
| Feller, AC | 1 |
| Trümper, L | 2 |
| Hasenclever, D | 1 |
| Wulf, G | 1 |
| Schmitz, N | 7 |
| Isidori, A | 1 |
| Christofides, A | 1 |
| Visani, G | 2 |
| Illerhaus, G | 1 |
| Kasenda, B | 1 |
| Ihorst, G | 2 |
| Egerer, G | 1 |
| Lamprecht, M | 1 |
| Keller, U | 1 |
| Wolf, HH | 1 |
| Hirt, C | 1 |
| Stilgenbauer, S | 1 |
| Binder, M | 1 |
| Hau, P | 1 |
| Edinger, M | 1 |
| Frickhofen, N | 1 |
| Bentz, M | 1 |
| Möhle, R | 2 |
| Röth, A | 1 |
| von Baumgarten, L | 1 |
| Deckert, M | 1 |
| Hader, C | 1 |
| Fricker, H | 1 |
| Valk, E | 1 |
| Schorb, E | 1 |
| Fritsch, K | 1 |
| Finke, J | 1 |
| Damaj, G | 1 |
| Cornillon, J | 1 |
| Bouabdallah, K | 1 |
| Gressin, R | 1 |
| Vigouroux, S | 2 |
| Gastinne, T | 2 |
| Ranchon, F | 1 |
| Ghésquières, H | 1 |
| Yakoub-Agha, I | 1 |
| Gyan, E | 2 |
| Wildes, TM | 1 |
| Augustin, KM | 1 |
| Sempek, D | 1 |
| Zhang, QJ | 1 |
| Vij, R | 1 |
| Dipersio, JF | 1 |
| McCann, S | 2 |
| Schwenkglenks, M | 2 |
| Bacon, P | 2 |
| Einsele, H | 2 |
| D'Addio, A | 2 |
| Maertens, J | 2 |
| Niederwieser, D | 2 |
| Roosaar, A | 2 |
| Ruutu, T | 2 |
| Schouten, H | 2 |
| Stone, R | 2 |
| Vorkurka, S | 1 |
| Quinn, B | 2 |
| Blijlevens, N | 2 |
| Zaucha, R | 1 |
| Gooley, T | 1 |
| Holmberg, L | 1 |
| Gopal, AK | 1 |
| Press, O | 1 |
| Maloney, D | 1 |
| Bensinger, WI | 2 |
| Ozturk, M | 1 |
| Komurcu, S | 1 |
| Kilic, S | 1 |
| Ozet, A | 1 |
| Arpaci, F | 1 |
| Ozturk, B | 1 |
| Kuzhan, O | 1 |
| Ataergin, S | 1 |
| Seshadri, T | 1 |
| Pintilie, M | 1 |
| Kuruvilla, J | 1 |
| Keating, A | 2 |
| Tsang, R | 1 |
| Zadeh, S | 1 |
| Crump, M | 3 |
| Barosi, G | 1 |
| Fanti, S | 1 |
| Gianni, AM | 1 |
| Martelli, M | 2 |
| Petrini, M | 1 |
| Zinzani, PL | 2 |
| Tura, S | 3 |
| Qiao, W | 1 |
| Zhao, J | 1 |
| Wang, C | 1 |
| Wang, T | 1 |
| Xing, Y | 1 |
| Liu, HW | 1 |
| Seftel, MD | 1 |
| Rubinger, M | 1 |
| Szwajcer, D | 1 |
| Demers, A | 1 |
| Nugent, Z | 1 |
| Schroeder, G | 1 |
| Butler, JB | 1 |
| Cooke, A | 1 |
| Rifkin, R | 2 |
| Spitzer, G | 1 |
| Orloff, G | 1 |
| Mandanas, R | 1 |
| McGaughey, D | 1 |
| Zhan, F | 1 |
| Boehm, KA | 1 |
| Asmar, L | 1 |
| Beveridge, R | 1 |
| Tran, L | 1 |
| Baars, JW | 1 |
| Aarden, L | 1 |
| Beijnen, JH | 1 |
| Huitema, AD | 1 |
| Rüping, MJ | 1 |
| Keulertz, C | 1 |
| Vehreschild, JJ | 1 |
| Lövenich, H | 1 |
| Söhngen, D | 1 |
| Wieland, U | 1 |
| Cornely, OA | 1 |
| Harris, RE | 1 |
| Termuhlen, AM | 1 |
| Smith, LM | 1 |
| Lynch, J | 1 |
| Henry, MM | 1 |
| Perkins, SL | 1 |
| Gross, TG | 1 |
| Warkentin, P | 1 |
| Vlachos, A | 1 |
| Harrison, L | 1 |
| Cairo, MS | 1 |
| Kim, JE | 1 |
| Lee, DH | 1 |
| Yoo, C | 1 |
| Kim, S | 2 |
| Kim, SW | 2 |
| Lee, JS | 2 |
| Park, CJ | 2 |
| Huh, J | 2 |
| Suh, C | 2 |
| Laack, NN | 1 |
| O'Neill, BP | 1 |
| Ballman, KV | 1 |
| O'Fallon, JR | 1 |
| Carrero, XW | 1 |
| Kurtin, PJ | 1 |
| Scheithauer, BW | 1 |
| Brown, PD | 1 |
| Colgan, JP | 1 |
| Gilbert, MR | 1 |
| Hawkins, RB | 1 |
| Morton, RF | 1 |
| Windschitl, HE | 1 |
| Fitch, TR | 1 |
| Pajon, ER | 1 |
| Samaras, P | 1 |
| Buset, EM | 1 |
| Siciliano, RD | 1 |
| Haile, SR | 1 |
| Petrausch, U | 1 |
| Mischo, A | 1 |
| Honegger, H | 2 |
| Pestalozzi, BC | 1 |
| Schanz, U | 1 |
| Stussi, G | 1 |
| Stahel, RA | 2 |
| Knuth, A | 1 |
| Renner, C | 1 |
| Stenner-Liewen, F | 1 |
| Monjanel, H | 1 |
| Perrodeau, E | 1 |
| Delwail, V | 1 |
| Moreau, A | 3 |
| François, S | 1 |
| Berthou, C | 1 |
| Milpied, N | 4 |
| Pielichowski, W | 1 |
| Barzal, J | 1 |
| Gawronski, K | 2 |
| Mlot, B | 1 |
| Oborska, S | 2 |
| Wasko-Grabowska, A | 2 |
| Rzepecki, P | 2 |
| Barzał, J | 1 |
| Młot, B | 1 |
| Szczylik, C | 1 |
| Avivi, I | 1 |
| Rowe, JM | 2 |
| Yeshurun, M | 2 |
| Levi, I | 1 |
| Or, R | 1 |
| Patachenko, P | 1 |
| Avigdor, A | 2 |
| Zwas, T | 1 |
| Nagler, A | 3 |
| Waibel Pachinger, C | 1 |
| Rosselet, A | 1 |
| Berthouzoz, S | 1 |
| Luthi, F | 1 |
| Ketterer, N | 1 |
| Tendas, A | 1 |
| Cupelli, L | 1 |
| Bruno, A | 1 |
| Niscola, P | 1 |
| De Angelis, V | 1 |
| Datturi, T | 1 |
| Cantoni, F | 1 |
| De Meis, I | 1 |
| Dentamaro, T | 1 |
| de Fabritiis, P | 1 |
| Kruger, PC | 1 |
| Cooney, JP | 1 |
| Turner, JH | 1 |
| Jang, GD | 1 |
| Suh, CW | 1 |
| Kim, EK | 1 |
| Bahng, HS | 1 |
| Jeong, YH | 1 |
| Park, IG | 1 |
| Kim, WK | 1 |
| Kim, SH | 1 |
| Suh, EJ | 1 |
| Ji, HS | 1 |
| Robinson, SP | 1 |
| Goldstone, AH | 4 |
| Mackinnon, S | 1 |
| Carella, A | 1 |
| de Elvira, CR | 1 |
| Taghipour, G | 1 |
| Kaiser, U | 1 |
| Uebelacker, I | 1 |
| Abel, U | 1 |
| Schmalenberg, H | 1 |
| Karakas, T | 1 |
| Metzner, B | 1 |
| Hossfeld, DK | 1 |
| Bischoff, HG | 1 |
| Franke, A | 1 |
| Reiser, M | 2 |
| Müller, P | 1 |
| Mantovani, L | 1 |
| Grundeis, M | 1 |
| Rothmann, F | 1 |
| von Seydewitz, CU | 1 |
| Mesters, RM | 1 |
| Steinhauer, EU | 1 |
| Krahl, D | 1 |
| Schumacher, K | 1 |
| Kneba, M | 1 |
| Baudis, M | 1 |
| Pfab, R | 1 |
| Köppler, H | 1 |
| Parwaresch, R | 1 |
| Havemann, K | 1 |
| Aleĭnikova, OV | 1 |
| Strongin, IuS | 1 |
| Pochetukhin, KV | 1 |
| Alekseeva, IuA | 3 |
| Zaritskiĭ, AIu | 3 |
| Medvedeva, NV | 3 |
| Mikhaĭlova, NB | 3 |
| Zubarovskaia, LS | 3 |
| Afanas'ev, BV | 3 |
| Arellano-Rodrigo, E | 1 |
| López-Guillermo, A | 4 |
| Nomdedeu, B | 2 |
| Montserrat, E | 1 |
| Rossi, HA | 1 |
| Becker, PS | 1 |
| Emmons, RV | 1 |
| Westervelt, P | 1 |
| Levy, W | 1 |
| Liu, Q | 1 |
| Clark, Y | 1 |
| Ballen, K | 1 |
| Laport, GG | 2 |
| Levine, BL | 1 |
| Stadtmauer, EA | 1 |
| Schuster, SJ | 1 |
| Luger, SM | 1 |
| Grupp, S | 1 |
| Bunin, N | 1 |
| Strobl, FJ | 1 |
| Cotte, J | 1 |
| Zheng, Z | 1 |
| Gregson, B | 1 |
| Rivers, P | 1 |
| Vonderheide, RH | 1 |
| Liebowitz, DN | 1 |
| Porter, DL | 1 |
| June, CH | 1 |
| Østby, I | 1 |
| Rusten, LS | 1 |
| Kvalheim, G | 2 |
| Grøttum, P | 1 |
| Jantunen, E | 4 |
| Kuittinen, T | 3 |
| Nousiainen, T | 4 |
| Mead, G | 1 |
| Woodcock, J | 1 |
| Young, C | 1 |
| Abrey, LE | 1 |
| Moskowitz, CH | 2 |
| Mason, WP | 1 |
| Stewart, D | 1 |
| Forsyth, P | 1 |
| Paleologos, N | 1 |
| Correa, DD | 1 |
| Anderson, ND | 1 |
| Caron, D | 1 |
| Zelenetz, A | 1 |
| Nimer, SD | 2 |
| DeAngelis, LM | 1 |
| Harder, H | 1 |
| Holtel, H | 1 |
| Bromberg, JE | 1 |
| Poortmans, P | 1 |
| Haaxma-Reiche, H | 1 |
| Kluin-Nelemans, HC | 1 |
| Menten, J | 1 |
| van den Bent, MJ | 1 |
| Dawson, LA | 1 |
| Saito, NG | 1 |
| Ratanatharathorn, V | 1 |
| Uberti, JP | 1 |
| Adams, PT | 1 |
| Ayash, LJ | 1 |
| Reynolds, CM | 1 |
| Silver, SM | 1 |
| Schipper, MJ | 1 |
| Lichter, AS | 1 |
| Eisbruch, A | 1 |
| Lewis, SA | 1 |
| Villa, S | 3 |
| Verger, E | 2 |
| Petit, J | 2 |
| Laporte, JP | 5 |
| Fouillard, L | 4 |
| Labopin, M | 2 |
| Cailliot, C | 1 |
| Lesage, S | 2 |
| Isnard, F | 4 |
| Najman, A | 4 |
| Gorin, NC | 5 |
| Debiais, S | 1 |
| Bonnaud, I | 1 |
| Cottier, JP | 1 |
| Destrieux, C | 1 |
| Saudeau, D | 1 |
| de Toffol, B | 1 |
| Arbion, F | 1 |
| Benboubker, L | 1 |
| Autret, A | 1 |
| Enke, C | 1 |
| Hankins, J | 1 |
| Bociek, G | 1 |
| Lynch, JC | 2 |
| Wadhwa, PD | 2 |
| Koc, ON | 2 |
| Fox, RM | 1 |
| Bajor, DL | 1 |
| Bedi, T | 1 |
| Laughlin, MJ | 2 |
| Payne, J | 1 |
| Rigacci, L | 1 |
| Carrai, V | 1 |
| Nassi, L | 1 |
| Alterini, R | 1 |
| Longo, G | 1 |
| Bernardi, F | 1 |
| Bosi, A | 1 |
| Wójcik, B | 1 |
| Kowalczyk, JR | 1 |
| Chybicka, A | 1 |
| Wachowiak, J | 1 |
| Drabko, K | 1 |
| Zaucha-Prazmo, A | 1 |
| Choma, M | 1 |
| Gorczyńska, E | 1 |
| Toporski, J | 1 |
| Turkiewicz, D | 1 |
| Kałwak, K | 1 |
| Pieczonka, A | 1 |
| Boruczkowski, D | 1 |
| Rao, PS | 1 |
| Prince, HM | 2 |
| Regester, G | 1 |
| Gates, P | 1 |
| Jablonskis, L | 1 |
| Seymour, JF | 1 |
| Lillie, K | 1 |
| West, R | 1 |
| Wolf, M | 1 |
| Januszewicz, H | 1 |
| Belford, D | 1 |
| Jabbour, E | 1 |
| Peslin, N | 1 |
| Arnaud, P | 1 |
| Ferme, C | 1 |
| Carde, P | 1 |
| Vantelon, JM | 1 |
| Bocaccio, C | 1 |
| Clavio, M | 1 |
| Garrone, A | 1 |
| Pierri, I | 1 |
| Michelis, GL | 1 |
| Balocco, M | 1 |
| Albarello, A | 1 |
| Varaldo, R | 1 |
| Canepa, P | 1 |
| Miglino, M | 1 |
| Ballerini, F | 1 |
| Canepa, L | 1 |
| Gobbi, M | 1 |
| Robertson, MJ | 1 |
| Abonour, R | 1 |
| Hromas, R | 1 |
| Nelson, RP | 1 |
| Fineberg, NS | 1 |
| Cornetta, K | 1 |
| Husso-Saastamoinen, M | 1 |
| Sipola, P | 1 |
| Vuolteenaho, O | 2 |
| Ala-Kopsala, M | 2 |
| Hartikainen, J | 2 |
| Assouline, S | 1 |
| Sylvestre, MP | 1 |
| Carriere, P | 1 |
| Shustik, C | 1 |
| Stewart, DA | 1 |
| Bahlis, N | 1 |
| Valentine, K | 1 |
| Balogh, A | 1 |
| Savoie, L | 1 |
| Morris, DG | 1 |
| Jones, A | 1 |
| Brown, C | 1 |
| Russell, JA | 1 |
| Law, LY | 1 |
| Horning, SJ | 6 |
| Wong, RM | 3 |
| Johnston, LJ | 2 |
| Lowsky, R | 1 |
| Shizuru, JA | 2 |
| Blume, KG | 6 |
| Negrin, RS | 6 |
| Stockerl-Goldstein, KE | 3 |
| Vanninen, E | 1 |
| Mussalo, H | 1 |
| Ernst, S | 1 |
| Bühlmann, M | 1 |
| Stucki, A | 1 |
| Bükki, J | 1 |
| Stanga, Z | 1 |
| Atta, J | 1 |
| Chow, KU | 1 |
| Weidmann, E | 1 |
| Mitrou, PS | 1 |
| Hoelzer, D | 1 |
| Martin, H | 1 |
| Zwas, ST | 1 |
| Oksman, Y | 1 |
| Hardan, I | 1 |
| Shem-Tov, N | 1 |
| Yerushalmi, R | 1 |
| Ben-Bassat, I | 1 |
| Huang, HQ | 1 |
| Cai, QQ | 1 |
| Lin, XB | 1 |
| Wang, BF | 1 |
| Bu, Q | 1 |
| Gao, Y | 1 |
| Peng, YL | 1 |
| Michallet, M | 1 |
| Porcher, R | 1 |
| Attal, M | 2 |
| Ades, L | 1 |
| Bernard, M | 1 |
| Blaise, D | 2 |
| Tabrizi, R | 1 |
| Garban, F | 1 |
| Cassuto, JP | 1 |
| Chevalier, P | 1 |
| Facon, T | 1 |
| Ifrah, N | 1 |
| Renaud, M | 1 |
| Vernant, JP | 1 |
| Kuentz, M | 1 |
| Bordigoni, P | 1 |
| Lioure, B | 1 |
| Socié, G | 1 |
| van Heeckeren, WJ | 1 |
| Bajor, DJ | 1 |
| Xu, Z | 1 |
| Jo, JC | 1 |
| Kang, BW | 1 |
| Jang, G | 1 |
| Sym, SJ | 1 |
| Lee, SS | 1 |
| Koo, JE | 1 |
| Kim, JW | 1 |
| Strobel, ES | 1 |
| Bauchmüller, K | 1 |
| Engelhardt, M | 1 |
| Krishnan, A | 1 |
| Fung, HC | 1 |
| Raubitschek, AA | 1 |
| Molina, A | 2 |
| Yamauchi, D | 1 |
| Rodriguez, R | 1 |
| Spielberger, RT | 1 |
| Falk, P | 1 |
| Mesters, R | 1 |
| Schubert, J | 1 |
| Boogaerts, M | 1 |
| Johnsen, HE | 1 |
| Canizo, CD | 1 |
| Baker, N | 1 |
| Barker, P | 1 |
| Skacel, T | 1 |
| Vokurka, S | 1 |
| Portlock, CS | 1 |
| Maruyama, Y | 1 |
| Feola, JM | 1 |
| Muir, W | 1 |
| Philip, T | 5 |
| Guglielmi, C | 4 |
| Hagenbeek, A | 4 |
| Somers, R | 4 |
| Van der Lelie, H | 1 |
| Bron, D | 3 |
| Sonneveld, P | 1 |
| Gisselbrecht, C | 7 |
| Cahn, JY | 2 |
| Harousseau, JL | 3 |
| Thomas, PS | 1 |
| Agrawal, S | 1 |
| Gore, M | 1 |
| Geddes, DM | 1 |
| Sniecinski, I | 1 |
| Schmidt, GM | 1 |
| Dagis, AC | 1 |
| O'Donnell, MR | 1 |
| Snyder, DS | 1 |
| Parker, PM | 1 |
| Stein, AS | 1 |
| Smith, EP | 1 |
| Haioun, C | 3 |
| Lepage, E | 4 |
| Coiffier, B | 6 |
| Bosly, A | 3 |
| Morel, P | 4 |
| Nouvel, C | 2 |
| Herbrecht, R | 2 |
| D'Agay, MF | 1 |
| Cortelazzo, S | 3 |
| Viero, P | 3 |
| Bellavita, P | 3 |
| Rossi, A | 3 |
| Buelli, M | 2 |
| Borleri, GM | 1 |
| Marziali, S | 1 |
| Bassan, R | 3 |
| Comotti, B | 3 |
| Rambaldi, A | 3 |
| Kusnierz-Glaz, CR | 1 |
| Still, BJ | 1 |
| Schriber, JR | 2 |
| Chao, NJ | 3 |
| Long, GD | 5 |
| Hoyle, C | 1 |
| Hu, WW | 3 |
| Brown, BW | 2 |
| Dranitsaris, G | 1 |
| Sutcliffe, SB | 1 |
| Dreger, P | 3 |
| Klöss, M | 1 |
| Petersen, B | 1 |
| Haferlach, T | 1 |
| Löffler, H | 2 |
| Scheid, C | 2 |
| Pettengell, R | 1 |
| Ghielmini, M | 1 |
| Radford, JA | 1 |
| Morgenstern, GR | 1 |
| Stern, PL | 1 |
| Crowther, D | 2 |
| Reyes, F | 2 |
| Vaughan, WP | 2 |
| Kris, E | 1 |
| Vose, J | 2 |
| Gwilt, P | 1 |
| Khwaja, A | 1 |
| Linch, DC | 4 |
| Demirer, T | 1 |
| Weaver, CH | 3 |
| Buckner, CD | 3 |
| Petersen, FB | 1 |
| Sanders, J | 1 |
| Clift, RA | 1 |
| Lilleby, K | 1 |
| Anasetti, C | 1 |
| Martin, P | 1 |
| Mills, W | 1 |
| Chopra, R | 1 |
| McMillan, A | 1 |
| Moreau, P | 2 |
| LeTortorec, S | 1 |
| Mahé, MA | 1 |
| Mahé, B | 2 |
| Bourdin, S | 1 |
| Bulabois, CE | 2 |
| Bureau, B | 1 |
| Adkins, DR | 1 |
| Salzman, D | 1 |
| Boldt, D | 1 |
| Kuhn, J | 1 |
| Irvin, R | 1 |
| Roodman, GD | 1 |
| Lyons, R | 1 |
| Smith, L | 1 |
| LeMaistre, CF | 1 |
| Schlaifer, D | 1 |
| Huguet, F | 1 |
| Canal, P | 1 |
| Laurent, G | 1 |
| Pris, J | 1 |
| Wheeler, C | 3 |
| Strawderman, M | 1 |
| Ayash, L | 1 |
| Churchill, WH | 2 |
| Bierer, BE | 1 |
| Elias, A | 2 |
| Gilliland, DG | 1 |
| Antman, K | 1 |
| Guinan, EC | 1 |
| Eder, JP | 1 |
| Gryn, J | 1 |
| Gordon, R | 1 |
| Bapat, A | 1 |
| Goldman, N | 1 |
| Goldberg, J | 1 |
| Patti, C | 1 |
| Majolino, I | 1 |
| Scimè, R | 1 |
| Indovina, A | 1 |
| Vasta, S | 1 |
| Liberti, G | 1 |
| Gentile, S | 1 |
| Santoro, A | 1 |
| Pisa, R | 1 |
| Caronia, F | 1 |
| Jones, RB | 2 |
| Matthes, S | 2 |
| Shpall, EJ | 2 |
| Fisher, JH | 1 |
| Stemmer, SM | 1 |
| Dufton, C | 1 |
| Stephens, JK | 1 |
| Bearman, SI | 2 |
| Bergeron, C | 1 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Chatel, M | 1 |
| Edan, C | 1 |
| Patte, C | 1 |
| Faivre, J | 1 |
| Smith, RJ | 1 |
| Sweetenham, JW | 1 |
| Boogaerts, MA | 1 |
| Ferrant, A | 1 |
| Demuynck, HM | 1 |
| Link, H | 1 |
| Zander, A | 1 |
| Barge, A | 1 |
| Punt, JA | 1 |
| Firth, JL | 1 |
| Hope, DT | 1 |
| Moloney, AJ | 1 |
| Vignetti, M | 1 |
| Gherlinzoni, F | 2 |
| Meloni, G | 1 |
| Fiacchini, M | 1 |
| De Sanctis, V | 1 |
| Papa, G | 1 |
| Martelli, MF | 1 |
| Calabresi, F | 1 |
| Mandelli, F | 1 |
| Haas, R | 1 |
| Moos, M | 1 |
| Döhner, H | 1 |
| Witt, B | 1 |
| Goldschmidt, H | 1 |
| Murea, S | 1 |
| Flentje, M | 1 |
| Wannenmacher, M | 1 |
| Hunstein, W | 1 |
| Barbui, T | 2 |
| Fracassetti, D | 1 |
| Marchioli, R | 2 |
| Marfisi, RM | 2 |
| Caballero, MD | 2 |
| Amigo, ML | 1 |
| Hernández, JM | 1 |
| Vazquez, L | 2 |
| del Cañizo, C | 2 |
| Gonzalez, M | 3 |
| García, R | 1 |
| San Miguel, JF | 3 |
| Stiff, P | 1 |
| Gordon, MS | 1 |
| McNiece, I | 1 |
| Ho, AD | 1 |
| Costa, JJ | 1 |
| Broun, ER | 1 |
| Bayer, RA | 1 |
| Wyres, M | 1 |
| Hill, J | 1 |
| Jelaca-Maxwell, K | 1 |
| Nichols, CR | 1 |
| Brown, SL | 1 |
| Gabrilove, J | 1 |
| Jost, LM | 1 |
| Betts, E | 1 |
| Goebel, ME | 1 |
| Vaughan Hudson, B | 1 |
| Anderson, L | 1 |
| Vaughan Hudson, G | 1 |
| von Neuhoff, N | 1 |
| Kuse, R | 1 |
| Sonnen, R | 1 |
| Glass, B | 1 |
| Uharek, L | 1 |
| Bartels, H | 1 |
| Girouard, C | 1 |
| Dufresne, J | 1 |
| Imrie, K | 1 |
| Stewart, AK | 1 |
| Brandwein, J | 1 |
| Pantolony, D | 1 |
| Rubio, V | 2 |
| Rifon, J | 2 |
| Heras, I | 2 |
| García-Sanz, R | 2 |
| Vidriales, B | 2 |
| del Cañizo, MC | 1 |
| Corral, M | 1 |
| León, A | 2 |
| Jean-Paul, E | 2 |
| Rocha, E | 2 |
| Moraleda, JM | 1 |
| Pedersen-Bjergaard, J | 1 |
| Pedersen, M | 1 |
| Myhre, J | 1 |
| Geisler, C | 1 |
| Caballero, D | 1 |
| Pérez-Simón, JA | 1 |
| Vicente, V | 1 |
| Stiff, PJ | 1 |
| Dahlberg, S | 1 |
| McCall, AR | 1 |
| Nademanee, AP | 1 |
| LeBlanc, M | 1 |
| Fisher, RI | 1 |
| Schwartzberg, L | 1 |
| Rhinehart, S | 1 |
| West, J | 1 |
| Zhen, B | 2 |
| West, WH | 1 |
| Salloum, E | 2 |
| Jillella, AP | 2 |
| Nadkarni, R | 2 |
| Seropian, S | 2 |
| Hu, GL | 2 |
| D'Andrea, E | 1 |
| Zelterman, D | 2 |
| Cooper, DL | 2 |
| Aurlien, E | 1 |
| Holte, H | 1 |
| Pharo, A | 1 |
| Kvaløy, S | 1 |
| Jakobsen, E | 1 |
| Smeland, EB | 1 |
| Voillat, L | 1 |
| Colombat, P | 2 |
| Rapp, MJ | 1 |
| Dupas, B | 1 |
| Juge-Morineau, N | 1 |
| Douay, L | 3 |
| Lopez, M | 1 |
| Aoudjhane, M | 1 |
| Zunic, P | 1 |
| Cheron, N | 1 |
| Stachowiak, J | 2 |
| Lemonnier, MP | 1 |
| Andreu, G | 1 |
| Belkacemi, Y | 1 |
| Noël-Walter, MP | 1 |
| Fenaux, P | 1 |
| Jouet, JP | 1 |
| Bauters, F | 1 |
| Korfel, A | 1 |
| Thiel, E | 1 |
| Blay, J | 1 |
| Gomez, F | 1 |
| Bachelot, T | 1 |
| Biron, P | 2 |
| Chauvin, F | 2 |
| Re, D | 1 |
| Bamborschke, S | 1 |
| Feiden, W | 1 |
| Schröder, R | 1 |
| Lehrke, R | 1 |
| Diehl, V | 2 |
| Tesch, H | 2 |
| Nieto, Y | 1 |
| Xu, X | 1 |
| Cagnoni, PJ | 1 |
| Murphy, J | 1 |
| Burtness, B | 1 |
| Josting, A | 1 |
| Dias Wickramanayake, P | 1 |
| Draube, A | 1 |
| Wolf, J | 1 |
| Kiss, I | 1 |
| Tomasek, J | 1 |
| Dix, S | 1 |
| Cord, M | 1 |
| Howard, S | 1 |
| Coon, J | 1 |
| Belt, R | 1 |
| Geller, R | 1 |
| Damiani, D | 1 |
| Grimaz, S | 1 |
| Infanti, L | 1 |
| Sperotto, A | 1 |
| Silvestri, F | 1 |
| Geromin, A | 1 |
| Cerno, M | 1 |
| Savignano, C | 1 |
| Michieli, M | 1 |
| Skert, C | 1 |
| Fanin, R | 1 |
| Baccarani, M | 2 |
| Uyl-de Groot, CA | 1 |
| Ossenkoppele, GJ | 1 |
| Buijt, I | 1 |
| Huijgens, PC | 1 |
| Stein, RS | 1 |
| Greer, JP | 1 |
| Goodman, S | 1 |
| Brandt, SJ | 1 |
| Morgan, DS | 1 |
| Macon, WR | 1 |
| McCurley, TL | 1 |
| Wolff, SN | 1 |
| Volk, J | 1 |
| Kleine, HD | 1 |
| Buthmann, U | 1 |
| Freund, M | 1 |
| Vela-Ojeda, J | 1 |
| Tripp-Villanueva, F | 1 |
| Montiel-Cervantes, L | 1 |
| Sánchez-Cortés, E | 1 |
| Ayala-Sánchez, M | 1 |
| Guevara-Moreno, ME | 1 |
| García-León, LD | 1 |
| Rosas-Cabral, A | 1 |
| Esparza, MA | 1 |
| González-Llaven, J | 1 |
| Alvarnas, JC | 1 |
| Stockerl-Goldstein, K | 1 |
| Tierney, K | 1 |
| Wong, R | 1 |
| Berglund, A | 1 |
| Enblad, G | 1 |
| Carlson, K | 1 |
| Glimelius, B | 1 |
| Hagberg, H | 1 |
| Brice, P | 2 |
| Lederlin, P | 1 |
| Brière, J | 1 |
| Gaulard, P | 1 |
| Mahlamäki, E | 1 |
| Reddy, SA | 1 |
| Horning, SF | 1 |
| Chao, NF | 1 |
| Johnston, LF | 1 |
| Strober, S | 1 |
| Feiner, RH | 1 |
| Kobler, S | 1 |
| Faucher, C | 1 |
| Vey, N | 1 |
| Caraux, J | 1 |
| Maraninchi, D | 1 |
| Chabannon, C | 1 |
| Carella, AM | 1 |
| Cavaliere, M | 1 |
| Lerma, E | 1 |
| Ferrara, R | 1 |
| Tedeschi, L | 1 |
| Romanelli, A | 1 |
| Vinci, M | 1 |
| Pinotti, G | 1 |
| Lambelet, P | 1 |
| Loni, C | 1 |
| Verdiani, S | 1 |
| De Stefano, F | 1 |
| Valbonesi, M | 1 |
| Corsetti, MT | 1 |
| Protheroe, AS | 1 |
| Pickard, C | 1 |
| Johnson, PW | 1 |
| Craddock, T | 1 |
| Shefta, J | 1 |
| Short, K | 1 |
| Lancaster, F | 1 |
| Selby, PJ | 1 |
| Henwood, J | 1 |
| Boylston, AW | 1 |
| Dumontet, C | 1 |
| Thieblemont, C | 1 |
| Espinouse, D | 1 |
| Bouafia, F | 1 |
| Hequet, O | 1 |
| Holland, I | 2 |
| Khurshid, A | 1 |
| Ibrahim, J | 1 |
| Mauch, P | 1 |
| Ault, K | 1 |
| Antin, J | 1 |
| Lacy, MQ | 1 |
| Markovic, SN | 1 |
| Stuart, MJ | 1 |
| Chao, NS | 1 |
| Becherer, A | 1 |
| Mitterbauer, M | 1 |
| Jaeger, U | 1 |
| Greinix, HT | 1 |
| Karanikas, G | 1 |
| Pötzi, C | 1 |
| Raderer, M | 1 |
| Dudczak, R | 1 |
| Kletter, K | 1 |
| Sharp, G | 1 |
| Chan, WC | 1 |
| Nichols, C | 1 |
| Loh, K | 1 |
| Inwards, D | 1 |
| Weisenburger, DD | 2 |
| Kessinger, A | 3 |
| Zappasodi, P | 1 |
| Vitulo, P | 1 |
| Volpini, E | 1 |
| Castagnola, C | 1 |
| Nascimbene, C | 1 |
| Corso, A | 1 |
| Bennett, JM | 2 |
| Lenhard, RE | 1 |
| Ezdinli, E | 2 |
| Johnson, GJ | 2 |
| Carbone, PP | 2 |
| Pocock, SJ | 1 |
| Durant, JR | 1 |
| Gams, RA | 1 |
| Bartolucci, AA | 1 |
| Dorfman, RF | 1 |
| Schorer, AE | 1 |
| Oken, MM | 1 |
| Icli, F | 1 |
| Ezdinli, EZ | 2 |
| Costello, W | 1 |
| Berard, CW | 1 |
| Kaufman, JH | 1 |
| Aungst, CW | 2 |
| Stutzman, L | 1 |
| Jochimsen, PR | 1 |
| Pearlman, NW | 1 |
| Lawton, RL | 1 |
| Marolleau, JP | 1 |
| Dombret, H | 1 |
| Baruchel, A | 1 |
| Adam, M | 1 |
| Miclea, JM | 1 |
| Sitthy, X | 1 |
| Lee, SM | 1 |
| Scarffe, JH | 1 |
| Dougal, M | 1 |
| Elder, RH | 1 |
| Rafferty, JA | 1 |
| Margison, GP | 1 |
| Reed, EC | 1 |
| Glenn, LD | 1 |
| Eugene-Jolchine, I | 1 |
| Punt, J | 1 |
| Firth, J | 1 |
| Hope, T | 1 |
| Lowe, J | 1 |
| Spiers, AS | 1 |
| Weens, JH | 1 |
| Smith, TJ | 1 |
| Horton, J | 1 |
| Gordon, LI | 1 |
| Glick, JH | 1 |
| Kluin Nelemans, JC | 2 |
| Misset, JL | 1 |
| Van der Lely, J | 1 |
| Moormeier, JA | 1 |
| Williams, SF | 1 |
| Kaminer, LS | 1 |
| Garner, M | 1 |
| Bitran, JD | 1 |
| Hoppe, RT | 1 |
| Kwak, LW | 1 |
| Stallbaum, B | 1 |
| O'Connor, P | 1 |
| Misset, JC | 1 |
| Herve, P | 1 |
| Lamagnere, JP | 1 |
| Schouten, HC | 1 |
| Maragos, D | 1 |
| Antin, JH | 1 |
| Come, SE | 1 |
| Smith, BR | 1 |
| Bubley, GJ | 1 |
| Rosenthal, DS | 1 |
| Rappaport, JM | 1 |
| Ault, KA | 1 |
| Schnipper, LE | 1 |
| Ribera, JM | 1 |
| Grañena, A | 1 |
| Rozman, C | 1 |
| Urbano-Ispizua, A | 1 |
| Bladé, J | 1 |
| Carreras, E | 1 |
| Cervantes, F | 1 |
| Marín, P | 1 |
| Sierra, J | 1 |
| Smith, DM | 1 |
| Landmark, JD | 1 |
| Harrington, DP | 1 |
| Kucuk, O | 1 |
| Silverstein, MW | 1 |
| Anderson, J | 1 |
| O'Connell, MJ | 2 |
| de Andrea, ML | 1 |
| de Camargo, B | 1 |
| Correa Alves, A | 1 |
| Machado, JC | 1 |
| Franco, EL | 1 |
| Mazza, P | 1 |
| Ricci, P | 1 |
| Bandini, G | 1 |
| Zaccaria, A | 1 |
| Rosti, G | 1 |
| Lauria, F | 1 |
| Donadio, D | 1 |
| Navarro, M | 1 |
| Izarn, P | 1 |
| Sullivan, MP | 1 |
| Boyett, J | 1 |
| Pullen, J | 1 |
| Crist, W | 1 |
| Doering, EJ | 1 |
| Trueworthy, R | 1 |
| Hvizdala, E | 1 |
| Ruymann, F | 1 |
| Steuber, CP | 1 |
| Drewinko, B | 1 |
| Gottlieb, JA | 1 |
| Schein, PS | 1 |
| Blom, J | 1 |
| Hubbard, S | 1 |
| Magrath, IT | 1 |
| Bergevin, P | 1 |
| Wiernik, PH | 1 |
| Ziegler, JL | 1 |
| DeVita, VT | 1 |
| De Vita, VT | 1 |
| Canellos, GP | 1 |
| Schein, PJ | 1 |
| Chabner, BA | 1 |
| Bagley, CM | 1 |
| Young, RC | 1 |
| Shapiro, WR | 1 |
| Chernik, NL | 1 |
| Posner, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studio Osservazionale Retrospettivo Multicentrico Sull'Utilizzo di Ibrutinib in Monoterapia o in Associazione a Immunochemioterapia Secondo Schema R-CHOP in Pazienti Adulti Con Diagnosi di PCNSL Ricaduto o Refrattario[NCT05782374] | 36 participants (Anticipated) | Observational | 2022-08-10 | Recruiting | |||
| A Phase II, Multicenter, Prospective, Non-randomised, Open-label, Clinical Trial to Evaluate Effectiveness and Safety of BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation[NCT03315520] | Phase 2 | 100 participants (Anticipated) | Interventional | 2016-01-22 | Recruiting | ||
| Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation[NCT00647049] | Phase 2 | 78 participants (Anticipated) | Interventional | 2007-01-31 | Recruiting | ||
| A Pilot Study of Peripheral Blood Stem Cell Transplantation (PBSCT) After Preparative Therapy Consisting of Cyclophosphamide, BCNU, and Etoposide (CBV) for Recurrent and Primarily Refractory Hodgkin's and Non-Hodgkin's Lymphoma[NCT00002941] | Phase 2 | 69 participants (Actual) | Interventional | 1998-04-30 | Completed | ||
| PHASE II TRIAL OF CHEMOTHERAPY PLUS RADIOTHERAPY FOR MANAGEMENT OF PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN'S LYMPHOMA (PCNSL)[NCT00002676] | Phase 2 | 36 participants (Actual) | Interventional | 1995-07-31 | Completed | ||
| Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas[NCT00869284] | Phase 2 | 45 participants (Actual) | Interventional | 1994-10-31 | Completed | ||
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)[NCT00003061] | Phase 2 | 50 participants (Anticipated) | Interventional | 1997-07-31 | Completed | ||
| Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma[NCT01208896] | Phase 2 | 32 participants (Actual) | Interventional | 2011-02-03 | Completed | ||
| A Single Center, Prospective Study to Compare the Quality and Quantity of the Cellular Content of M-PRP Harvested After Peripheral Mobilization of Progenitor Cells Using Filgrastim Versus Pegfilgrastim[NCT05573386] | 10 participants (Anticipated) | Observational | 2021-08-09 | Recruiting | |||
| A Randomised, Multi-Centre, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Non-Hodgkin's Lymphoma[NCT00117455] | Phase 2 | 0 participants | Interventional | Completed | |||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia[NCT04303520] | Phase 1 | 20 participants (Anticipated) | Interventional | 2018-05-03 | Recruiting | ||
| Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence[NCT02681302] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-06-07 | Active, not recruiting | ||
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial[NCT05786989] | Phase 4 | 32 participants (Anticipated) | Interventional | 2023-02-28 | Recruiting | ||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)[NCT02278796] | Phase 2 | 108 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma[NCT01466868] | Phase 2 | 22 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions) | ||
| Targeted Intensification by a New Preparative Regimen for Patients With Low-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose Beam Followed by Autologous Stem Cell Tran[NCT00138086] | Phase 2 | 75 participants | Interventional | 2005-03-31 | Completed | ||
| Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab[NCT00137995] | Phase 3 | 481 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)[NCT00144807] | Phase 2 | 128 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Study of R-ACVBP Regimen Supported by Pegfilgrastim in Previously Untreated Patients Aged From 18 to 60 Years With High-Risk Diffuse Large B-Cell Lymphoma (Age-adjusted Ipi >or= 2)[NCT00169143] | Phase 2 | 60 participants | Interventional | 2004-05-31 | Completed | ||
| Randomised Phase 3 Study of Rituximab in High-Risk Patients With Diffuse Large B-Cell Lymphoma Who Received a First-Line Consolidative Chemotherapy With Autologous Stem Cell Transplant (ASCT).[NCT00169169] | Phase 3 | 430 participants | Interventional | 1999-10-31 | Terminated | ||
| Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation[NCT00001830] | Phase 1 | 110 participants (Actual) | Interventional | 1999-07-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
9 reviews available for carmustine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2015 |
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; D | 2016 |
Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Hematopoietic St | 2017 |
Non-hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Mo | 2003 |
Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabi | 2007 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Mo | 1999 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dru | 1972 |
77 trials available for carmustine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos | 2022 |
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Car | 2018 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; | 2014 |
Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autografts; Car | 2014 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hemat | 2016 |
Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytara | 2016 |
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous | 2016 |
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabin | 2010 |
Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cyc | 2011 |
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclo | 2011 |
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2011 |
Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex | 2011 |
Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Phosphates; Carmustine; Cytarabine; E | 2011 |
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Prot | 2012 |
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide | 2002 |
[Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexa | 2002 |
High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blood Plate | 2003 |
[Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dex | 2003 |
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Pro | 2003 |
BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 2003 |
Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 2004 |
Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined | 2005 |
High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Drug Resistance, | 2005 |
Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Hematopoiet | 2005 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cyta | 2006 |
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Com | 2007 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Com | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Movement; Cohort | 1994 |
Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1994 |
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Coh | 1995 |
Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blo | 1995 |
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fever; Granulocyt | 1995 |
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone | 1993 |
Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1994 |
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera | 1996 |
High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter s
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1996 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmu | 1996 |
Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1996 |
Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colony-Forming Units Assay; Cyclo | 1997 |
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1997 |
Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1997 |
Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1997 |
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality | 1997 |
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Caus | 1998 |
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Thera | 1998 |
Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1998 |
Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neopl | 1999 |
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Drug R | 1999 |
Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 2000 |
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryopreservation; Cyc | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ble | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; C | 2000 |
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 2000 |
CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2001 |
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2001 |
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 2002 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.
Topics: Carmustine; Cell Cycle; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Therapy, Combin | 1977 |
Lymphosarcoma. A comparison of extended to conservative chemotherapy.
Topics: Adult; Aged; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; | 1976 |
GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1991 |
Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; D | 1991 |
The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisp | 1991 |
PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1991 |
[Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1990 |
The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1987 |
Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded).
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow; Carmustine; Child; Child, Preschool; C | 1985 |
Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).
Topics: Adenoma, Islet Cell; Blood Cells; Burkitt Lymphoma; Carcinoid Tumor; Carmustine; Clinical Trials as | 1974 |
119 other studies available for carmustine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combi | 2021 |
Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System; Central Ne | 2022 |
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste | 2023 |
BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Ther | 2019 |
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central | 2020 |
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System; Central Nervous | 2020 |
Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous Syste | 2021 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; | 2018 |
BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; | 2019 |
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; | 2019 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2014 |
[Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cy | 2015 |
Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Topics: Adult; Biosimilar Pharmaceuticals; Carmustine; Female; Filgrastim; Granulocyte Colony-Stimulating Fa | 2014 |
Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2015 |
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug | 2015 |
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgk
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Fol | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyta | 2015 |
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carmustine; Creatinine; Cytarabine | 2015 |
LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
Topics: Adolescent; Adult; Autografts; Carmustine; Child; Child, Preschool; Cohort Studies; Cyclophosphamide | 2016 |
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Su | 2008 |
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protoco | 2009 |
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busu | 2008 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy | 2009 |
Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hema | 2009 |
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine | 2010 |
Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclo | 2010 |
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
Topics: Adult; Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2010 |
Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Cytokines; Female; He | 2011 |
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administra | 2010 |
Acute coronary syndrome upon receiving carmustine infusion before autologous stem-cell transplantation.
Topics: Acute Coronary Syndrome; Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neopl | 2012 |
Single-dose pegylated-filgrastim versus daily filgrastim after high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies: delayed platelets recovery?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carmustine; Cytarabine | 2012 |
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocy | 2002 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2002 |
[High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].
Topics: Adolescent; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 2002 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2003 |
A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.
Topics: Adult; Algorithms; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carm | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Cognitive status and quality of life after treatment for primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Carmustine; Case-Control Stud | 2004 |
Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Centr | 2004 |
A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combina | 2004 |
A spinal cord intravascular lymphomatosis with exceptionally good outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capillaries; Carmustine; Central Nervous Syste | 2004 |
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyt | 2005 |
[Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; | 2004 |
[Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 2004 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2005 |
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Topics: Adult; Aged; Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmust | 2005 |
Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm | 2005 |
Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular System; Carmustine; Cycl | 2005 |
Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carm | 2006 |
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Combined Modality | 2006 |
Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Natriuretic Factor; Biomarkers; | 2006 |
[What is your diagnosis? Neutropenic colitis (neutropenic typhlitis)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cecum; Colon; Combined Modality Therapy; | 2007 |
Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytara | 2007 |
[Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation].
Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics, Opioid; Antineoplastic Combined Chemothera | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Prot | 2007 |
Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Disease-Free Sur | 2008 |
BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyt | 2008 |
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2008 |
Management of the indolent non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1980 |
1,3-bis(2-chloroethyl)-1-nitrosourea treatment of spontaneous radiogenic C57BL mouse leukemia/lymphoma.
Topics: Animals; Carmustine; Leukemia Virus, Murine; Leukemia, Radiation-Induced; Lymphoma; Lymphoma, Non-Ho | 1983 |
Recall lung pneumonitis due to carmustine after radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Female; Humans; Lymphoma, Non-Hodgkin; Middle Aged; P | 1995 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marr | 1995 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; | 1995 |
Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1995 |
Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chem | 1994 |
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1993 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cis | 1993 |
High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colo | 1993 |
Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplat | 1993 |
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; | 1995 |
Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Eto | 1997 |
Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etop | 1997 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1997 |
BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1997 |
[Autologous transplant with BEAM protocol in lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytara | 1997 |
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 1998 |
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 1998 |
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxo | 1998 |
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Combined Mod | 1998 |
Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Carmustine; Centra | 1998 |
Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Topics: Adult; Ambulatory Care; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carm | 1999 |
Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; | 1999 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1999 |
Autologous bone marrow transplantation in non-Hodgkin's lymphoma patients: effect of a brief course of G-CSF on harvest and recovery.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmu | 1999 |
Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Bone Marrow Tra | 1999 |
Oxidative burst measurement in patients treated with cytostatics: influence of G-CSF and role as a prognostic factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine | 2000 |
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carm | 2000 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Co | 2000 |
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; California; Carmustine; Cos | 2000 |
Rescue of haemopoiesis by a combination of growth factors including stem-cell factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carm | 2000 |
Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue.
Topics: Amino Acid Sequence; Antineoplastic Agents, Alkylating; Bone Marrow Purging; Breast Neoplasms; Carci | 2000 |
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 2001 |
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Topics: Adjuvants, Immunologic; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 2002 |
Successful therapy with high-dose steroids and cyclosporine for the treatment of carmustine-mediated lung injury.
Topics: Adult; Antineoplastic Agents, Alkylating; Carmustine; Cyclosporine; Dose-Response Relationship, Drug | 2002 |
Gynecomastia with nitrosourea therapy.
Topics: Adult; Aged; Carmustine; Gynecomastia; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle | 1978 |
Diffuse well-differentiated lymphocytic lymphoma (DLWD): response and survival.
Topics: Aged; Antineoplastic Agents; Carmustine; Cell Differentiation; Chlorambucil; Cyclophosphamide; Drug | 1978 |
Pancreatic carcinoma as a sequel to therapy of lymphoma.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Agents; Carmustine; Cyclophosphamide; Female; Hodg | 1976 |
Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Ca | 1992 |
Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation.
Topics: Acrolein; Adenosine Triphosphatases; Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Cyc | 1992 |
High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplanta | 1992 |
Primary non-Hodgkin's lymphoma of the central nervous system: phase II study of chemotherapy (BVAM) prior to radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; | 1991 |
High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies.
Topics: Adult; Alkylating Agents; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Hematopoi | 1990 |
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Mo | 1991 |
BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1990 |
Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Diabetes Mellitus; Dos | 1990 |
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1990 |
Recombinant human granulocyte-macrophage colony-stimulating factor plus the beam regimen instead of autologous bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stim | 1989 |
High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfu | 1989 |
Factors of prognostic importance in childhood non-Hodgkin's lymphoma treated with two modified LSA2-L2 protocols. A multivariate analysis approach.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; C | 1988 |
High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantati | 1986 |
[Neuromeningeal localizations in acute leukemia and non-Hodgkin's lymphoma. Protocol combining BCNU-cytosine arabinoside].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cytarabi | 1987 |
The response of synchronized human lymphoma cells to bleomycin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Bleomycin; Carmustine; Cell Division; Cell Line; Cell Survival; Cells, Cultured; Dose-Response Relat | 1973 |
Treatment of Hodgkin's disease and other malignant lymphomas.
Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; | 1973 |
Necrotizing encephalopathy following intraventricular instillation of methotrexate.
Topics: Adolescent; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Cerebral Ventr | 1973 |